María Teresa Gómez Casares-rekin lankidetzan egindako argitalpenak (30)

2024

  1. Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia

    Frontiers in Oncology, Vol. 14

  2. Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study

    Annals of Hematology, Vol. 103, Núm. 10, pp. 4045-4055

  3. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  4. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  5. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

    Leukemia

  6. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

2023

  1. Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

    HemaSphere, Vol. 7, Núm. 8, pp. E936

  2. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE

    British Journal of Haematology, Vol. 202, Núm. 5, pp. 942-952

2022

  1. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239

  2. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

    Cancer, Vol. 128, Núm. 13, pp. 2441-2448

2021

  1. Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea

    Leukemia, Vol. 35, Núm. 2, pp. 623-627

2020

  1. Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis

    Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158

  2. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

    Leukemia and Lymphoma, Vol. 61, Núm. 3, pp. 650-659

  3. Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes

    Journal of Molecular Diagnostics, Vol. 22, Núm. 10, pp. 1217-1224

  4. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis

    Annals of Hematology, Vol. 99, Núm. 4, pp. 791-798

  5. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk

    Leukemia, Vol. 34, Núm. 10, pp. 2648-2659

2018

  1. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

    British Journal of Haematology

  2. Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase (Journal of Cancer Research and Clinical Oncology, (2017), 143, 10, (2059-2066), 10.1007/s00432-017-2445-z)

    Journal of Cancer Research and Clinical Oncology

  3. Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

    Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098

  4. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

    Journal of Cancer Research and Clinical Oncology, Vol. 144, Núm. 5, pp. 945-954